phase 3

Targets
Pharma

ESC: Cytokinetics data is first to demonstrate benefit for nHCM

New Cytokinetics data showed first-of-its-kind benefits in a rare heart condition, potentially teeing the company up for a watershed FDA approval.
Donavyn Coffey Aug 28, 2026 5:50am
globe asia

China IIT, Daiichi Sankyo-AZ, Leo-Tanabe—Fierce Pharma Asia

Aug 21, 2026 9:00am
feet

Trial results set up Keenova to gain 3rd indication for Xiaflex

Jul 8, 2026 11:27am
Close up shot of the target from a dart game

Argenx's Vyvgart posts ph. 3 win in ocular myasthenia gravis

Feb 26, 2026 11:18am
bacteria and virus science on chalkboard
Favicon Fierce Biotech

US vaccine landscape ‘100%’ impacting business: Bancel

Jan 23, 2026 1:26pm
accelerated

IntraBio's Aqneursa tees up 2nd rare disease nod with ph. 3 win

Jan 21, 2026 11:48am